Page 9 - ப்ராடக்ட் பண்புகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ப்ராடக்ட் பண்புகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ப்ராடக்ட் பண்புகள் Today - Breaking & Trending Today

Investegate |Diurnal Group PLC Announcements | Diurnal Group PLC: Distribution agreement with Er-Kim

Investegate |Diurnal Group PLC Announcements | Diurnal Group PLC: Distribution agreement with Er-Kim
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

Foster Mitchell , Emma Earl , Cem Zorlular , Freddy Crossley , Martin Whitaker , Richard Bungay , Alex Davis , Simon Conway , Rupert Dearden , European Union , Panmure Gordon United Kingdom Limited Nominated Adviser , European Commission , Diurnal Group , Middle East , Chief Executive Officer , Chief Executive , Chief Financial , United Kingdom , Nominated Adviser , Sole Broker , Investor Relations , Product Characteristics , Congenital Adrenal Hyperplasia , United Kingdom Headquartered , வளர்ப்பு மிட்செல் , எம்மா ஏர்ல் ,

IP Group plc (via Public) / Diurnal Group plc - Distribution agreement with Er-Kim for Bulgaria and Romania

IP Group plc (via Public) / Diurnal Group plc - Distribution agreement with Er-Kim for Bulgaria and Romania
publicnow.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from publicnow.com Daily Mail and Mail on Sunday newspapers.

Foster Mitchell , Emma Earl , Cem Zorlular , Freddy Crossley , Martin Whitaker , Richard Bungay , Alex Davis , Simon Conway , Rupert Dearden , European Union , Panmure Gordon United Kingdom Limited Nominated Adviser , European Commission , Diurnal Group , Middle East , Chief Executive Officer , Chief Executive , Chief Financial , United Kingdom , Nominated Adviser , Sole Broker , Investor Relations , Product Characteristics , Congenital Adrenal Hyperplasia , United Kingdom Headquartered , வளர்ப்பு மிட்செல் , எம்மா ஏர்ல் ,

Diurnal (AIM:DNL) | RNS | Diurnal Group PLC - Distribution agreement with Er-Kim

Diurnal (AIM:DNL) | RNS | Diurnal Group PLC - Distribution agreement with Er-Kim
proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.

Foster Mitchell , Emma Earl , Cem Zorlular , Freddy Crossley , Martin Whitaker , Richard Bungay , Alex Davis , Simon Conway , Rupert Dearden , European Union , Panmure Gordon United Kingdom Limited Nominated Adviser , European Commission , Diurnal Group , Chief Executive Officer , Chief Executive , Chief Financial , United Kingdom , Nominated Adviser , Sole Broker , Investor Relations , Product Characteristics , Congenital Adrenal Hyperplasia , வளர்ப்பு மிட்செல் , எம்மா ஏர்ல் , ஃப்ரெடி குறுக்கு , மார்டின் வைட்டேக்கர் ,

taiba Middle East FZ LLC Announces a Commercialization and Distribution Agreement With Insmed for ARIKAYCE® in the Countries of GCC (Kingdom of Saudi Arabia, UAE, Kuwait, Oman, Qatar, Bahrain).

Published: Jun 14, 2021
DUBAI, United Arab Emirates (BUSINESS WIRE)
taiba Middle East, a leading regional pharmaceutical company specializing in orphan and rare diseases in the region of Middle East/North Africa, announces that
Insmed Netherlands BV, a subsidiary of Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, has granted taiba exclusive rights to market and distribute ARIKAYCE® in the Countries of Gulf Cooperation Council (Saudi Arabia, UAE, Kuwait, Oman, Qatar, Bahrain).
Under the terms of the agreement, taiba will be responsible for the named patient supply program with intent to commercialize ARIKAYCE in the region following receipt of marketing authorization(s) in the territory. ....

United Arab Emirates , United States , United Kingdom , Saudi Arabia , Neil Hughes , Saif Al Hasani , European Union , Insmed Incorporated , Countries Of Gulf Cooperation Council Saudi Arabia , Gulf Cooperation Council Region , United Arab , Middle East , North Africa , Insmed Netherlands , Gulf Cooperation Council , Orphan Drug Designation , Breakthrough Therapy Designation , Qualified Infectious Disease Product , General Manager , Nebuliser Dispersion , Product Characteristics , ஒன்றுபட்டது அரபு அமீரகங்கள் , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , சவுதி அரேபியா , நீல் ஹக்ஸ் ,

Sanofi: Dupixent (dupilumab) SmPC updated with long-term data reinforcing well-established safety profile in adults with moderate-to-severe atopic dermatitis

Sanofi: Dupixent (dupilumab) SmPC updated with long-term data reinforcing well-established safety profile in adults with moderate-to-severe atopic dermatitis
in adults with moderate-to-severe atopic dermatitis
Dupixent is the first and only available systemic treatment for atopic dermatitis that has been studied in adults for up to 3 years in a Phase 3 trial
PARIS and TARRYTOWN, N.Y. - June
28
,
2021- Long-term safety data from a study of adults with moderate-to-severe atopic dermatitis treated with Dupixent will be added to the Dupixent Summary of Product Characteristics (SmPC) following a positive opinion issued by the European Medicines Agency s Committee for Medicinal Products for Human Use. ....

United States , France General , Eva Schaefer Jansen , Arnaud Delepine , Suzanne Greco , Felix Lauscher , Mark Hudson , Fara Berkowitz , Hannah Kwagh , Nathalie Pham , Sally Bain , Exchange Commission , Regeneron Pharmaceuticals Inc , Regeneron Genetics Center , Dupilumab Development Program , Teva Pharmaceutical Industries Ltd , Dupixent Summary , Product Characteristics , European Medicines Agency , Medicinal Products , Investor Relations , Private Securities Litigation Reform Act , Statement Regarding Forward Looking , Forward Looking Statements , Digital Media , Regeneron Pharmaceuticals ,